Pharmceutical companies settle with hemophiliacs who contracted HIV/AIDs through blood products.

MASAC issues recommendations for prophylaxis treatment for individuals with r factor VIII or r factor IX.

The World Health Organization and the World Federation of Hemophilia recommend prophylaxis as the treatment of choice in children with hemophilia, based on evidence-driven studies.

Dr. Jeanne Lusher becomes the first female chair of MASAC.

The camp subcommittee of NHF's Nursing Executive Committee develops the first Hemophilia Camp Program Standards.

A coalition of hemophiliacs who contracted HIV/AIDS due to improper guidance from pharmaceutical companies and NHF around blood safety file a class action lawsuit.

NHF enters a co-op agreement with the CDC to provide education, resources, and programming.

In 1993, the FDA issued a new guideline and formally rescinded the 1977 policy that banned most women from participating in studies. To ensure that the policies for inclusion were firmly implemented by NIH, the Congress made what had previously been policy into law, through a section in the NIH Revitalization Act of 1993.

Dr. Glenn Pierce, a physician with hemophilia, runs for NHF president on a platform of reforming the organization to meet the community’s demands. Pierce appointed Val Bias, a MANN leader, as chairman of the board once elected.

The first recombinant factor VIII (8) product is approved by the Food and Drug Administration (FDA).